Latest From Glycotope GMBH
Daiichi teams with Glycotope on an antibody-drug conjugate for cancer, while Alector will partner with AbbVie to research antibody targets for Alzheimer’s disease.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.
ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Gynecological, Urological
- Western Europe
- Parent & Subsidiaries
- Glycotope GMBH
- Senior Management
Henner Kollenberg, Mng. Dir. & CFO
Alfredo Zurlo, MD, CMO
- Contact Info
Phone: (49) 30 9489 2600
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.